- Framework of problems / Rigourous
- Risk of bias not incorporated into conclusions of review
- Reporting of adverse events of treatment interventions in multiple myeloma: an overview of systematic reviews
Ref ID | 1038 |
First Author | M. Mainou |
Journal | ANNALS OF HEMATOLOGY |
Year Of Publishing | 2024 |
URL | https://link.springer.com/article/10.1007/s00277-023-05517-7 |
Keywords |
Harms Oncology Low methodological quality |
Problem(s) |
No registered or published protocol Low methodological (AMSTAR) quality Risk of bias not incorporated into conclusions of review Conflicts of interest or funding of included studies not assessed Reasons for excluding potentially eligible studies not provided |
Number of systematic reviews included | 23 |
Summary of Findings | Of the 23 included 7 SRs ,14.7% examined cardiovascular adverse events, 9 focused on infections, 3 studied thromboembolism and 4 more reviews focused on bortezomib-associated neurotoxicity, carfilzomib-associated renal toxicity, or second primary malignancies. The quality of included studies as judged by AMSTAR 2 was mostly critically low. None of the reviews provided a list of excluded studies, or reported on the sources of funding of studies, only 1 review assessed the potential impact of risk of bias in individual studies on the results of the meta-analysis, and 9 reviews (39.1%) did not have an a priori registered protocol. |
Did the article find that the problem(s) led to qualitative changes in interpretation of the results? | Not Applicable |
Are the methods of the article described in enough detail to replicate the study? |